Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-20-000340
Filing Date
2020-01-03
Accepted
2020-01-03 18:04:34
Documents
1
Period of Report
2019-12-27

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 5371
  Complete submission text file 0000899243-20-000340.txt   8094
Mailing Address 60 WALL STREET NEW YORK NY 10005
Business Address 60 WALL STREET NEW YORK NY 10005 212-319-7600
Dainippon Sumitomo Pharma Co Ltd (Reporting) CIK: 0001446601 (see all company filings)

State of Incorp.: M0 | Fiscal Year End: 0331
Type: 3 | Act: 34 | File No.: 001-38667 | Film No.: 20507231

Mailing Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617
Business Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617 949-226-6029
Urovant Sciences Ltd. (Issuer) CIK: 0001740547 (see all company filings)

EIN.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 0331
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Business Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB (646) 802-3660
Sumitovant Biopharma Ltd. (Reporting) CIK: 0001798244 (see all company filings)

State of Incorp.: D0 | Fiscal Year End: 0331
Type: 3 | Act: 34 | File No.: 001-38667 | Film No.: 20507232

Mailing Address 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260
Business Address 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260 813-5543-5142
Sumitomo Chemical Co., Ltd. (Reporting) CIK: 0001798550 (see all company filings)

State of Incorp.: M0 | Fiscal Year End: 0331
Type: 3 | Act: 34 | File No.: 001-38667 | Film No.: 20507230